Fig 1.
Schematic description of transendothelial permeability assays.
(A) Diagram depicting method for Dextran assay protocol. (B) Diagram depicting the measurement using the TEER protocol.
Fig 2.
Effects of TNFα, IL-1β and LPS on occludin band-shift in hCMEC/D3 cells.
Cells were treated with or without TNFα (10 ng/mL) (A), IL-1β (10 ng/mL)(B) and LPS (100 ng/mL) (C) for 15, 30 min and 1, 2, 4, 6 hours. Cell lysates were collected and occludin and β-actin expression patterns were analyzed by immunoblotting assay as described in text. The density of upper band versus total upper and lower and normalized with β-actin was determined by measuring protein intensity as PIupper/PItotal/PIβ-actin. Results are mean ± SD from 4 or more experiments and data are analyzed by one-way ANOVA followed by Bonferroni post-tests (***P<0.001 compared with no treatment control).
Fig 3.
Effects of TNFα, IL-1β and LPS on p-ERK1/2 and p-p38MAPK expression in hCMEC/D3 cells.
Cells were treated with or without TNFα (A, B, C), IL-1β (D) and LPS (E) for 15, 30 min and 1, 2, 4, 6 hours. Cell lysates were collected and phospho-ERK1/2 (P- ERK), total ERK1/2 (T-ERK), phospho-p38MAPK (P-P38), total p38MAPK (T-P38) and β-actin expression pattern were analyzed by immunoblotting assay. Quantification of phospho-proteins was determined through assay of PIphospho/PItotal/PIβ-actin and then normalized to control. Results of (B) and (C) are mean ± SD from 4 or more experiments and data are analyzed by one-way ANOVA followed by Bonferroni post-tests **P<0.01, ***P<0.001 compared with no treatment control). Results of (D) and (E) are representation of two repeated experiments.
Fig 4.
TNFα-mediated occludin band-shift and phosphorylation of ERK1/2 and p38MAPK in hCMEC/D3 cells.
Cells were treated with or without TNFα (10 ng/mL) at 5, 10, 15, 30, 60 min (A). Cell lysates were collected and occludin, P- ERK, T-ERK, P-P38, T-P38 and β-actin expression pattern was analyzed by immunoblotting assay. Quantification of the proportion of occludin upper band were determined through PIupper/PItotal/PIβ-actin and then normalized to control (B). phospho-ERK1/2 (C) and phospho-p38MAPK (D) were similarly quantified and plotted. Results are mean ± SD from 3 or more experiments and data are analyzed by one-way ANOVA followed by Bonferroni post-tests (**P<0.01, ***P<0.001 compared with no treatment control).
Fig 5.
Effects of p-ERK1/2 and p-p38MAPK inhibitors on occludin band-shift in CMEC/D3 cells.
Cells were pretreated with or without 10 μM U0126 and 10 μM SB202190 for 15 min and then stimulated with or without 10 ng/mL TNFα for 15, 30, 60 min (A and C). (B) Testing the effects of inhibitors alone. Cell lysates were collected and occludin, P- ERK, T-ERK, P-p38, T-p38 and β-actin expression pattern was analyzed by immunoblotting assay. Quantification of the proportions of occludin upper band at 15 min of TNFα and with inhibitors (blots enclosed in brackets) were determined through PIupper /PItotal/PIβ-actin and then normalized to control. Results are mean ± SD from 4 or more experiments. Two-way ANOVA revealed significant main effects of TNFα and the inhibitors and a significant interaction (p<0.0001 for each). Bonferroni post-test showed significant differences between TNFα-treated groups as compared to their respective controls (as indicated by the letter “a”), SB202190 alone as compared to control/no inhibitors (as indicated by the letter “c”) and TNFα-treated groups with vs. without the inhibitors (as indicated by the letter “b”).
Fig 6.
Effects of TNFα on tyrosine and threonine phosphorylation of occludin.
hCMEC/D3 cells were treated with or without 10 ng/mL TNFα for 15 min. Cell lysates were mixed with anti-tyrosine or anti-threonine antibody conjugated with protein A beads and then phosphorylated proteins in cell lysates were pulled down. Occludin and β-actin expression pattern was analyzed by immunoblotting assay.
Fig 7.
Effects of TNFα, IL-1β and LPS on occludin expression and cell viability.
(A) hCMEC/D3 cells were treated with or without TNFα (10 ng/mL), IL-1β (10 ng/mL) and LPS (100 ng/mL) for 24 hours. Cell lysates were collected and occludin and β-actin expression pattern was analyzed by immunoblotting assay. Quantification of the protein band intensity was determined through PItotal/PIβ-actin and then normalized to control. Results are mean ± SD from 4 or more experiments and data are analyzed by one-way ANOVA followed by Bonferroni post-tests (***P<0.001 compared with no treatment control). (B) Cell viability was determined by the WST-1 assay. One-way ANOVA revealed no significant differences among the groups.
Fig 8.
Effects of p-ERK1/2 and p-p38MAPK inhibitors on TNFα-induced occludin expression in hCMEC/D3 cells.
(A) Initial testing for cell viability using WST-1 assay indicated toxicity of cells upon incubation (24h) with TNFα (10 ng/mL) in the presence of SB202190 at 10 μM but not at 2 μM. (B) Testing ability of U0126 (2 μM) and SB202190 (2 μM) to ameliorate the decrease in occludin expression upon exposure of TNFα for 24 h. Cell lysates were collected and occludin and β-actin expression pattern was analyzed by immunoblotting assay. Quantification of protein band intensity was determined through PItotal/PIβ-actin and then normalized to control. Results are mean ± SD from 5 or more experiments. Two-way ANOVA revealed a significant main effect of TNFα (p<0.0001) and the inhibitors (p = 0.0287). Bonferroni post-test showed significant differences between TNFα-treated groups as compared to their respective controls (as indicated by the letter “a”), and TNFα-treated groups with vs. without SB202190 (as indicated by the letter “b”).
Fig 9.
Effects of TNFα, IL-1β and LPS on morphology of hCMEC/D3 cells.
(A) Cells were treated with or without TNFα (10 ng/mL), IL-1β (10 ng/mL) and LPS (100 ng/mL) for 24 hours and observed under bright field microscope as described in text. Representative pictures were taken from different areas in the field. (B) Ten cells from each picture were randomly selected for measurement using the Image J protocol. Results are mean ± SD from 3 experiments. One-way ANOVA with Bonferroni post-test showed a significant difference (p<0.01) between control and TNFα. (C) Representative bright field photomicroscope pictures to assess effects of MEK1/2 and p-p38MAPK inhibitors on TNFα-induced morphological changes. Cells were pretreated with U0126 (2 μM) and SB202190 (2 μM) for 15 min prior to treatment with TNFα (10 ng/mL) for 24 h. (D) Results are analyzed as in (B). Data are expressed as the mean ± SD of three experiments. Two-way ANOVA showed a significant main effect of TNFα (p = 0.0013). The effects of the inhibitors were not significant.
Fig 10.
Effects of TNFα, IL-1β and LPS on paracellular permeability as measured by the Dextran and TEER assays.
(A) For the Dextran assay, cells were cultured in inserts for 24 h followed by applying fluorescent FITC-Dextran beads as described in Methods. (B) TEER was determined using an endothelial volt/ohm meter for TEER-EVOM2 as described in Methods. Permeability were determined through FI24h/FI0min (Fluorescence Intensity) and then normalized to control. Results are mean ± SD from 4 or more experiments and data are analyzed by one-way ANOVA followed by Bonferroni post-tests (*P<0.05, ***P<0.001 compared with no treatment control). (C and D) Assessing effects of p-ERK1/2 and p-p38MAPK inhibitors on TNFα-induced changes on paracellular permeability as measured by the Dextran (C) and TEER assays (D). Data are expressed as the mean ± SD of four or more experiments. The results were analyzed by two-way ANOVA, and a significant main effect of TNFα was revealed (p<0.0001 for each). The effects of the inhibitors were not significant.